Bensch et al. (2018) employed 89Zr-Trastuzumab PET/CT imaging as a means of evaluating the HER2 expression status of 7 breast tumor metastases not accessible for biopsy, enabling more reliable patient dosing. Here, ERBB2 is linked to breast neoplasm.